The Next Big Thing in Prostate Cancer: Neal Shore, Alicia Morgans, and Charles Ryan

March 1, 2019

In this conversation, Neal Shore, Alicia Morgans and Chuck Ryan discuss their views on what the next “big thing” is in prostate cancer and exciting new developments in 2019.  These advancements include a renewed look at the patient’s experience and point of view to integrate into treatment decision making.  The group sees continued research in race and genetic disparities and how these factors effect patient outcomes.  There are many other advancements in prostate cancer.  


Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation.

Alicia Morgans, MD Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Neal Shore, MD, FACS is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, and the Large Urology Group Practice Association.